Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 6/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1279962 | 1.00 | EPHA2 (0.47) | EPHA2EPHB4ERBB2SLC6A2SLC6A4 | |
| SCHEMBL12469220 | 0.92 | EPHA2 (0.44) | EPHA2EPHB4ERBB2SLC6A2SLC6A4 | |
| SCHEMBL12469221 | 0.92 | EPHA2 (0.44) | EPHA2EPHB4ERBB2SLC6A2SLC6A4 | |
| SCHEMBL1280939 | 0.92 | EPHA2 (0.44) | EPHA2EPHB4ERBB2SLC6A2SLC6A4 | |
| SCHEMBL15303426 | 0.89 | SLC6A2 (0.41) | EPHA2EPHB4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15303424 | 0.89 | SLC6A2 (0.41) | EPHA2EPHB4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15303698 | 0.89 | SLC6A2 (0.41) | EPHA2EPHB4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15303433 | 0.89 | SLC6A2 (0.41) | EPHA2EPHB4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1280270 | 0.88 | SCN9A (0.48) | EPHA2EPHB4ERBB2SCN9A | |
| SCHEMBL1279850 | 0.85 | EPHA2 (0.46) | EPHA2EPHB4ERBB2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | SLC6A2, MAOB, MAOA | EPHA2 3808/4885EPHB4 1827/4885ERBB2 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.